H

Hangzhou AGS MedTech Co Ltd
SSE:688581

Watchlist Manager
Hangzhou AGS MedTech Co Ltd
SSE:688581
Watchlist
Price: 60.47 CNY -5.07% Market Closed
Market Cap: 4.9B CNY
Have any thoughts about
Hangzhou AGS MedTech Co Ltd?
Write Note

Hangzhou AGS MedTech Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hangzhou AGS MedTech Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
H
Hangzhou AGS MedTech Co Ltd
SSE:688581
Cost of Revenue
-ÂĄ149.9m
CAGR 3-Years
-30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Cost of Revenue
-ÂĄ486.1m
CAGR 3-Years
-51%
CAGR 5-Years
-45%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Cost of Revenue
-ÂĄ3.7B
CAGR 3-Years
1%
CAGR 5-Years
-6%
CAGR 10-Years
-14%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Cost of Revenue
-ÂĄ12.8B
CAGR 3-Years
-15%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Cost of Revenue
-ÂĄ518.3m
CAGR 3-Years
-12%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Cost of Revenue
-ÂĄ5.9B
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hangzhou AGS MedTech Co Ltd
Glance View

Market Cap
4.9B CNY
Industry
Health Care

Hangzhou AGS MedTech Co., Ltd. engages in the research and development, manufacture, and sale of equipment in minimally invasive diagnosis and treat. The company is headquartered in Hangzhou, Zhejiang and currently employs 501 full-time employees. The company went IPO on 2023-05-19. The firm's main products are used in the field of digestive endoscopy diagnosis and treatment, and are divided into hemostatic closure, EMR/ESD, biopsy, ERCP and diagnosis and treatment instruments according to their therapeutic purposes. The hemostatic closure category includes clip devices and single-use bipolar high-frequency hemostats. Medical instruments include high-frequency surgical equipment, carbon dioxide gas supply devices for endoscopes, and water supply devices for endoscopes. The biopsy category includes single-use biopsy forceps and single-use graspers.

Intrinsic Value
86.8 CNY
Undervaluation 30%
Intrinsic Value
Price
H

See Also

What is Hangzhou AGS MedTech Co Ltd's Cost of Revenue?
Cost of Revenue
-149.9m CNY

Based on the financial report for Dec 31, 2023, Hangzhou AGS MedTech Co Ltd's Cost of Revenue amounts to -149.9m CNY.

What is Hangzhou AGS MedTech Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-30%

Over the last year, the Cost of Revenue growth was -26%. The average annual Cost of Revenue growth rates for Hangzhou AGS MedTech Co Ltd have been -30% over the past three years .

Back to Top